Cargando…

SAT-431 Parameters of Glucose Metabolism Independently Predict Post Glucose Load Growth Hormone Concentrations in Patients with Acromegaly

Background: In healthy subjects, growth hormone (GH) concentrations following an oral glucose suppression test (OGTT) are known to be under the impact of gender, age, BMI an estrogen use. To date, very few data exist on factors influencing nadir GH in patients with acromegaly. Methods: In the presen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Micko, Alexander, Schernthaner-Reiter, Marie, Marculescu, Rodrig, Wolfsberger, Stefan, Knosp, Engelbert, Luger, Anton, Vila, Greisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6552076/ http://dx.doi.org/10.1210/js.2019-SAT-431

Ejemplares similares

LBMON175 Nadir Growth Hormone Concentrations In Patients With Acromegaly Relate To Disease Activity, Glucose Metabolism, BMI And Sex
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2022)

MON-318 Acute, Life-Threatening and Perioperative Complications in Cushing’s Syndrome: Predictors and Outcomes
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2020)

Long-Term Corticotroph Function Following Cure of Cushing’s Syndrome
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2021)

OR06-05 Inadequate High Mitochondrial ATP-Synthesis Explains “Non-Fatty-Liver” in Patients with Acromegaly
por: Fellinger, Paul, et al.
Publicado: (2020)

SAT-451 Acromegaly and Thyroid Cancer
por: Danilowicz, Karina, et al.
Publicado: (2019)

SAT-257 Coexisting Craniopharyngioma and Acromegaly
por: Yang, Almira, et al.
Publicado: (2020)

Prevalence of Abnormal Glucose Metabolism in Acromegaly & Impact of Treatment Modalities on Glucose Metabolism
por: Khan, Sajjad Ali, et al.
Publicado: (2021)

SAT-267 Pregnancy in Acromegaly: Report of Five Cases
por: Burcea, Iulia Florentina, et al.
Publicado: (2020)

SAT-249 Polyarticular Osteoarthritis: A Disabling Manifestation of Acromegaly
por: Khan, Azkia, et al.
Publicado: (2020)

SAT-251 New Diagnosis of Acromegaly with DKA as Initial Presentation
por: Gundluru, Rajani, et al.
Publicado: (2020)

SAT-473 Acromegaly and Drug-Induced Parkinsonism Were Controlled by Lanreotide
por: Iwabuchi, Masayasu
Publicado: (2019)

SAT-LB48 Novel Genetic Variant of Carney Complex With Acromegaly
por: Cristiano, Elizabeth, et al.
Publicado: (2020)

SAT-471 Abnormal Thyroid Function Tests in Acromegaly: A Clinical Conundrum
por: Fernandes, Stuti, et al.
Publicado: (2019)

SAT-470 A Case of Acromegaly with Concomitant Hypercortisolism Presenting with Diabetic Ketoacidosis
por: Gonzales, Irish Judy
Publicado: (2019)

SAT-468 Conversion of a Non-Secreting to a Growth Hormone-Secreting Pituitary Adenoma: A Case of Rapid Development of Acromegaly
por: Motwani, Komal, et al.
Publicado: (2019)

SAT-259 Acromegaly by Pituitary Adenoma Associated with ACTH-Independent Cushing Syndrome by Adrenal Carcinoma: Case Report
por: Minuzzi, Ricardo Kunde, et al.
Publicado: (2020)

SAT-472 Increased Thyroid Cancer Risk in Acromegaly: A Report of 3 Cases
por: Jaisinghani, Priya, et al.
Publicado: (2019)

SAT-LB078 Acromegaly Disease Activity According to ACRODAT® in Spain: ACROVAL Study
por: Marazuela, Monica, et al.
Publicado: (2019)

THU064 Clinical, Radiological Characteristics And Response To Somatostatin Analogues Of Acromegaly Patients With Different Patterns Of Growth Hormone Response After Oral Glucose Load
por: Godlewska, Magdalena, et al.
Publicado: (2023)

SAT-LB60 Discordant Biological Parameters of Remission in Acromegaly Do Not Increase the Risk of Hypertension or Diabetes: A Study With the Liege Acromegaly Survey Database
por: Amodru, Vincent, et al.
Publicado: (2020)

OR32-5 Associations between Circulation Lipocalin 2, Body Composition, and Glucose Metabolism in Active Acromegaly
por: Zhang, Yan, et al.
Publicado: (2019)

OR23-06 Is the Improved Glucose Homeostasis in Patients with Acromegaly Treated with Pegvisomant Caused by Improved Glucagon Secretion?
por: Jørgensen, miss, Nanna Thurmann, et al.
Publicado: (2020)

SAT-436 Adjuvant Therapeutic Modalities in Acromegaly: Clinical Course and Factors Predicting Biochemical Controls
por: Jung, Hyein, et al.
Publicado: (2019)

Ectopic Cushing’s syndrome in a patient with inferior petrosal sinus sampling indicating pituitary‐dependent ACTH secretion
por: Micko, Alexander, et al.
Publicado: (2019)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

SAT-469 Empty Sella Making Big Changes: A Case of Acromegaly and Empty Sella Syndrome
por: Padniewski, Jessica, et al.
Publicado: (2019)

SAT-466 Cases of Acromegaly and Presumed Prolactinoma in Setting of Empty Sella Syndrome: Presentation and Management Implications
por: Uwaifo, Gabriel
Publicado: (2019)

SAT622 Matched Physician- And Patient-reported Responses Of Acromegaly Symptom Control: Comparisons From The Macro Registry
por: Geer, Eliza Brevoort, et al.
Publicado: (2023)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SAT-465 Somatostatin Receptor Ligand as Initial Therapy in a Patient with Pituitary Microadenoma and Acromegaly: Temporary Remission and Recurrence
por: Baby, Ann, et al.
Publicado: (2019)

SAT-428 Effect of Age, Body Mass Index, and Sex on the Performance of Macimorelin for the Diagnosis of Adult Growth Hormone Deficiency: A Post Hoc Analysis
por: Garcia, Jose, et al.
Publicado: (2019)

Factors predicting long-term comorbidities in patients with Cushing’s syndrome in remission
por: Schernthaner-Reiter, Marie Helene, et al.
Publicado: (2018)

SAT-435 Optimization of Pharmacological Treatment of Acromegaly: Impact on IGF-1 Levels Comparing Isolated Octreotide LAR and Combined Pharmacological Therapy
por: Naves, Luciana, et al.
Publicado: (2019)

SAT613 A Novel NF1 Mutation As The Underlying Cause Of Dysmorphic Features And Acromegaly In An Atypical Case Of Neurofibromatosis Type 1
por: Alsagheir, Osamah, et al.
Publicado: (2023)

SAT-240 Hypothalamic Lipoma and Growth Hormone Deficiency
por: Rochtus, Anne Maria, et al.
Publicado: (2020)

SAT-434 Patient Reported Outcome Data from Acromegaly Patients Treated with Injectable Somatostatin Analogues in Routine Clinical Practice: Preliminary Results
por: Geer, Eliza, et al.
Publicado: (2019)

MON-306 Acromegaly Comorbidity Costs, Quality of Life, and Mortality: Lifetime Comparisons for Controlled Acromegaly, Uncontrolled Acromegaly, and the General US Population
por: Whittington, Melanie D, et al.
Publicado: (2020)

SAT-438 Visceral and Marrow Adiposity in Patients with Acromegaly; Relationships to Disease Activity, Markers of Bone Turnover, Bone Mineral Density, and Peripheral Bone Microarchitecture
por: Kuker, Adriana, et al.
Publicado: (2019)

MON-431 Clinical Presentation of Metastases to the Pituitary: A Swedish Nationwide Study
por: Schill, Fredrika, et al.
Publicado: (2019)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_g705josb82s1q8ek981fm70dbq